Development of Ag-ZnO/AgO Nanocomposites Effectives for ILeishmania braziliensis/I Treatment

Tegumentary leishmaniasis (TL) is caused by parasites of the genus Leishmania. Leishmania braziliensis (L.b) is one of the most clinically relevant pathogens that affects the skin and mucosa, causing single or multiple disfiguring and life-threatening injuries. Even so, the few treatment options for...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2022-11, Vol.14 (12)
Main Authors: Barbosa, Rafaela Miranda, Obata, Malu Mateus Santos, Neto, José Rodrigues do Carmo, Guerra, Rhanoica Oliveira, Borges, Anna Victória Bernardes e, Trevisan, Rafael Obata, Ruiz, Letícia Cirelli, Bernardi, Júlia de Moura, Oliveira-Scussel, Ana Carolina de Morais, Tanaka, Sarah Cristina Sato Vaz, Vito, Fernanda Bernadelli de, Helmo, Fernanda Rodrigues, Assunção, Thaís Soares Farnesi de, Machado, Juliana Reis, Oliveira, Carlo José Freire de, Júnior, Virmondes Rodrigues, Silva, Anielle Christine Almeida, Silva, Marcos Vinicius da
Format: Article
Language:English
Subjects:
Antiparasitic agents
Chemical properties
Drug delivery systems
Drug therapy
Drugs
Gold
Health aspects
Leishmaniasis
Nanoparticles
Pharmaceutical research
Vehicles
Zinc oxide
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tegumentary leishmaniasis (TL) is caused by parasites of the genus Leishmania. Leishmania braziliensis (L.b) is one of the most clinically relevant pathogens that affects the skin and mucosa, causing single or multiple disfiguring and life-threatening injuries. Even so, the few treatment options for patients have significant toxicity, high dropout rates, high cost, and the emergence of resistant strains, which implies the need for studies to promote new and better treatments to combat the disease. Zinc oxide nanocrystals are microbicidal and immunomodulatory agents. Here, we develop new Ag-ZnO/xAgO nanocomposites (NCPs) with three different percentages of silver oxide (AgO) nanocrystals (x = 49%, 65%, and 68%) that could act as an option for tegumentary leishmaniasis treatment. Our findings showed that 65% and 68% of AgO inhibit the extra and intracellular replication of L.b. and present a high selectivity index. Ag-ZnO/65%AgO NCPs modulate activation, expression of surface receptors, and cytokine production by human peripheral blood mononuclear cells toward a proinflammatory phenotype. These results point to new Ag-ZnO/AgO nanocomposites as a promising option for L. braziliensis treatment.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14122642